Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (21-30 of 338) with videos related to

Pageof 34
Sort By:
Journal of Cancer Metastasis and Treatment|March 17, 2022
Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinomaMichael T Serzan, Michael B Atkins
Cancer Treatment Reviews|September 3, 2018
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinomaMichael B Atkins, Nizar M Tannir
Expert Opinion on Investigational Drugs|August 7, 2010
Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyondRyan J Sullivan, Michael B Atkins
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
New agents and new targets for renal cell carcinomaGeorge K Philips, Michael B Atkins
Cancer Medicine|January 10, 2014
PD-1 as a potential target in cancer therapyDavid F McDermott, Michael B Atkins
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Emerging clinical issues in melanoma in the molecularly targeted eraRyan J Sullivan, Michael B Atkins
Journal of Cutaneous Pathology|May 21, 2010
Cytokine therapy in melanomaRyan J Sullivan, Michael B Atkins
Journal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F Mcdermott
Expert Opinion on Emerging Drugs|August 20, 2016
Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)Michael B Atkins, George K Philips
Current Urology Reports|December 22, 2004
Chemotherapies and immunotherapies for metastatic kidney cancerYoo-Joung Ko, Michael B Atkins
Pageof 34

Showing results (21-30 of 338) with videos related to

Sort By:
Pageof 34
Journal of Cancer Metastasis and Treatment|March 17, 2022
Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinomaMichael T Serzan, Michael B Atkins
Cancer Treatment Reviews|September 3, 2018
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinomaMichael B Atkins, Nizar M Tannir
Expert Opinion on Investigational Drugs|August 7, 2010
Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyondRyan J Sullivan, Michael B Atkins
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
New agents and new targets for renal cell carcinomaGeorge K Philips, Michael B Atkins
Cancer Medicine|January 10, 2014
PD-1 as a potential target in cancer therapyDavid F McDermott, Michael B Atkins
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Emerging clinical issues in melanoma in the molecularly targeted eraRyan J Sullivan, Michael B Atkins
Journal of Cutaneous Pathology|May 21, 2010
Cytokine therapy in melanomaRyan J Sullivan, Michael B Atkins
Journal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F Mcdermott
Expert Opinion on Emerging Drugs|August 20, 2016
Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)Michael B Atkins, George K Philips
Current Urology Reports|December 22, 2004
Chemotherapies and immunotherapies for metastatic kidney cancerYoo-Joung Ko, Michael B Atkins
Pageof 34